PASTEUR Act

12/20/2024, 9:06 AM

Pioneering Antimicrobial Subscriptions To End Upsurging Resistance Act of 2023 or the PASTEUR Act of 2023

This bill authorizes the Department of Health and Human Services (HHS) to enter into subscription contracts for critical-need antimicrobial drugs, provides $6 billion in appropriations for activities under the bill, and contains other related provisions.

A manufacturer of a Food and Drug Administration-approved antimicrobial drug may apply to HHS to have the drug designated as a critical-need antimicrobial, and HHS may enter into a subscription contract for such a critical-need antimicrobial. The bill imposes certain requirements related to such contracts, including a mechanism to lower payments under the contract in certain instances to limit the manufacturer's revenue from the drug.

Furthermore, HHS and the Centers for Disease Control and Prevention (CDC) shall award grants to support efforts to encourage the appropriate use of antimicrobial drugs and efforts to combat antimicrobial resistance. The CDC shall also track and assess data relating to antibacterial resistance and human antibiotic use and make such data publicly available.

HHS shall also establish a Committee on Critical Need Antimicrobials. The committee shall develop a list of prioritized infections for which new antimicrobial drug development is needed, among other duties.

Within six years of the bill's enactment, the Government Accountability Office shall report to Congress a study on the bill's effectiveness in developing priority antimicrobial drugs.

The PASTEUR Act, also known as Bill 118 hr 2940, is a piece of legislation currently being considered by the US Congress. The purpose of this bill is to establish a program within the Department of Health and Human Services that would support research and development efforts to combat emerging infectious diseases.

Specifically, the PASTEUR Act aims to enhance the nation's preparedness for potential pandemics by investing in research on new vaccines, treatments, and diagnostics. The bill would provide funding for the development of medical countermeasures to address emerging infectious diseases, such as novel viruses or drug-resistant bacteria.

Additionally, the PASTEUR Act seeks to improve coordination between federal agencies, academic institutions, and private sector partners in order to streamline the research and development process. By fostering collaboration and information sharing, the bill aims to accelerate the development of new medical countermeasures and ensure that the United States is better equipped to respond to future public health threats. Overall, the PASTEUR Act represents a bipartisan effort to strengthen the nation's ability to respond to emerging infectious diseases and protect the health and safety of the American people. If passed, this legislation has the potential to significantly enhance our preparedness for future pandemics and save lives.
Congress
118

Number
HR - 2940

Introduced on
2023-04-27

# Amendments
0

Sponsors
+5

Cosponsors
+5

Variations and Revisions

4/27/2023

Status of Legislation

Bill Introduced
Introduced to House
House to Vote
Introduced to Senate
Senate to Vote

Purpose and Summary

Pioneering Antimicrobial Subscriptions To End Upsurging Resistance Act of 2023 or the PASTEUR Act of 2023

This bill authorizes the Department of Health and Human Services (HHS) to enter into subscription contracts for critical-need antimicrobial drugs, provides $6 billion in appropriations for activities under the bill, and contains other related provisions.

A manufacturer of a Food and Drug Administration-approved antimicrobial drug may apply to HHS to have the drug designated as a critical-need antimicrobial, and HHS may enter into a subscription contract for such a critical-need antimicrobial. The bill imposes certain requirements related to such contracts, including a mechanism to lower payments under the contract in certain instances to limit the manufacturer's revenue from the drug.

Furthermore, HHS and the Centers for Disease Control and Prevention (CDC) shall award grants to support efforts to encourage the appropriate use of antimicrobial drugs and efforts to combat antimicrobial resistance. The CDC shall also track and assess data relating to antibacterial resistance and human antibiotic use and make such data publicly available.

HHS shall also establish a Committee on Critical Need Antimicrobials. The committee shall develop a list of prioritized infections for which new antimicrobial drug development is needed, among other duties.

Within six years of the bill's enactment, the Government Accountability Office shall report to Congress a study on the bill's effectiveness in developing priority antimicrobial drugs.

The PASTEUR Act, also known as Bill 118 hr 2940, is a piece of legislation currently being considered by the US Congress. The purpose of this bill is to establish a program within the Department of Health and Human Services that would support research and development efforts to combat emerging infectious diseases.

Specifically, the PASTEUR Act aims to enhance the nation's preparedness for potential pandemics by investing in research on new vaccines, treatments, and diagnostics. The bill would provide funding for the development of medical countermeasures to address emerging infectious diseases, such as novel viruses or drug-resistant bacteria.

Additionally, the PASTEUR Act seeks to improve coordination between federal agencies, academic institutions, and private sector partners in order to streamline the research and development process. By fostering collaboration and information sharing, the bill aims to accelerate the development of new medical countermeasures and ensure that the United States is better equipped to respond to future public health threats. Overall, the PASTEUR Act represents a bipartisan effort to strengthen the nation's ability to respond to emerging infectious diseases and protect the health and safety of the American people. If passed, this legislation has the potential to significantly enhance our preparedness for future pandemics and save lives.
Alternative Names
Official Title as IntroducedTo amend title III of the Public Health Service Act to establish a program to develop antimicrobial innovations targeting the most challenging pathogens and most threatening infections, and for other purposes.

Policy Areas
Health

Potential Impact
Administrative law and regulatory procedures
Advanced technology and technological innovations
Advisory bodies
Appropriations
Department of Health and Human Services
Drug therapy
Executive agency funding and structure
Government information and archives
Government studies and investigations
Health information and medical records
Infectious and parasitic diseases
Medical research
Prescription drugs
Public contracts and procurement
Research and development

Comments

Recent Activity

Latest Summary1/9/2024

Pioneering Antimicrobial Subscriptions To End Upsurging Resistance Act of 2023 or the PASTEUR Act of 2023

This bill authorizes the Department of Health and Human Services (HHS) to enter into subscription cont...


Latest Action12/17/2024
Referred to the Subcommittee on Health.